Industry

SALT LAKE CITY–(BUSINESS WIRE)–iVeena Delivery Systems Inc. (“iVeena”), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) that grants Glaukos an exclusive global license to develop and commercialize IVMED-80, a pharmacologic treatment for keratoconus. Keratoconus, a rare corneal disorder, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Breast Cancer Clinical Trial Pipeline Highlights – 2022” report has been added to ResearchAndMarkets.com’s offering. The report provides the most up-to-date information on key pipeline products in the global Breast Cancer market. It covers emerging therapies for Breast Cancer in active clinical development stages including early and late stage clinical trials. The … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Peptide Therapeutics Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Peptide Therapeutics Market is projected to reach USD 50.72 billion by 2027 from USD 27.13 billion in 2021, at a CAGR 10.99% during the forecast period. In this report, the years 2019 and 2020 … [Read more…]

Company will analyze longitudinal biological samples and clinical data to identify molecular pathways associated with healthy longevity, leading to development of drug targets for diseases of aging RICHMOND, Calif.–(BUSINESS WIRE)–#aging–BioAge Labs, Inc. (“BioAge”, “the Company”), a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that … [Read more…]

From August 26th to 28th, 30 Korean companies exhibit and sell their excellent products in Jakarta, Indonesia CHEONGJU, South Korea & JAKARTA, Indonesia–(BUSINESS WIRE)–#2022ChungbukBestProductPromotion–Chungcheongbuk-do has started to secure export channels for promising exporters in North Chungcheong Province to the Indonesian market. 2022 CHUNGBUK BEST PRODUCT PROMOTION will be held by Chungcheongbuk-do and Chungbuk Business Agency … [Read more…]

Series B financing will accelerate growth and advance lead clinical program 212Pb-ADVC001 a best-in-class treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress internal and partnership programs. SYDNEY–(BUSINESS WIRE)–#AdvanCell–AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18 … [Read more…]

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the Investigational New Drug (IND) of CM369, an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody, developed by a joint venture between the two companies called Tiannuojiancheng Pharma, has been approved by the China’s National Medical Products Administration (NMPA). CM369 is a … [Read more…]

– Cases of Varicella infections have fallen by 92% in 10 years – Studies implies that the one-dose universal varicella vaccination program in Korea since 2005 has been successful in preventing chickenpox YONGIN, South Korea–(BUSINESS WIRE)–GC Biopharma (006280.KS) today announced that it will present new data demonstrating trends in the incidence of varicella cases with … [Read more…]

AUSTIN, Texas & LONDON–(BUSINESS WIRE)–Babylon Holdings Limited (NYSE:BBLN) (“Babylon” or the “Company”), one of the world’s fastest growing digital healthcare companies, announces that David Humphreys will be appointed as the Company’s new Chief Financial Officer. Mr. Humphreys has been at Babylon for nearly two years in the role of Finance Director, with overall responsibility for … [Read more…]

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), will host its inaugural R&D Day on Monday, September 26, 2022, from approximately 10:00 a.m. to 12:30 p.m. (ET) in Midtown, New York City. Anebulo’s … [Read more…]